Company Analysis
Sign in

Dogwood Therapeutics, Inc. (DWTX)

Nasdaq: DWTX · Pharmaceutical Preparations · Alpharetta, GA · filing with the SEC since 2020
Full chart Alerts Compare
Grade4.2
◀ Past 3.5● Present 4.8▶ Future 4.1
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$34.3M-177.4%
Earnings per share$-7.13+43.1%
Operating cash flow-$15.6M-77.7%
Cash$6.5M-56.1%
Debtn/a
Shareholders’ equity$74.9M+839.8%
Shares, diluted4,977,446+384.3%
Return on equity-45.7%
The recordfrom its filings
Filings in 202640
Newest filingNov 6 · EFFECT
Annual reportMar 18, 2026
Quarterly reportNov 6, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted2
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$25.2MCash from operations -$16.5Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 6, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Nov 6, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form S-3
Shelf registration
Open the filing on sec.gov
Oct 27, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 14, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton DWTX · research, not advice